Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Mar 8;22(1):31.
doi: 10.1186/s12981-025-00726-8.

Prevalence of Mpox vaccine acceptance and hesitancy among people living with HIV: a comprehensive systematic review and meta-analysis

Ambanna Yappalparvi #  1   2 , Mahalaqua Nazli Khatib #  3 , Ashok Kumar Balaraman  2 , M M Rekha  4 , Mandeep Kaur  5 , Girish Chandra Sharma  6 , Puneet Sudan  7 , K Satyam Naidu  8 , Rajesh Singh  9 , Sonam Ramashankar  10 , Karan Khati  11 , Sanjay Singh Chauhan  12 , Lokesh Verma  13 , Amritpal Sidhu  14 , Rachana Mehta  15 , Renu Sah  16   17   18 , Abhay M Gaidhane  19 , Muhammed Shabil  20   21 , Joseph Clement Chipeta  22 , Ganesh Bushi  23
Affiliations
Meta-Analysis

Prevalence of Mpox vaccine acceptance and hesitancy among people living with HIV: a comprehensive systematic review and meta-analysis

Ambanna Yappalparvi et al. AIDS Res Ther. .

Abstract

Background: Vaccine acceptance among People Living with HIV (PLWH) is crucial for managing and mitigating the spread of infectious diseases, including Mpox. This systematic review and meta-analysis assess the rate of vaccine acceptance for Mpox among PLWH and identify factors influencing these rates.

Methods: We searched major databases including PubMed, Embase, and Web of Science up to 30 August 2024 for observational studies involving PLWH that reported on mpox vaccine acceptance rates. A random-effects model was employed for the meta-analysis, utilizing R software version 4.4. Heterogeneity among the studies was quantified using the I² statistic, and the methodological quality of each study was assessed using a modified version of the Newcastle-Ottawa Scale.

Results: Out of 1,123 articles identified, 17 studies met the inclusion criteria and included 7,248 participants. The pooled estimate of the Mpox vaccine acceptance rate was 61.1% (95% CI: 44.2-75.7%), with high heterogeneity (I² = 99%). Additionally, a pooled vaccine hesitancy prevalence was 13.2%, (95% CI: 2.4-48.6%), reflecting substantial variability and had high heterogeneity (I² = 98%).

Conclusion: This systematic review and meta-analysis reveal moderate Mpox vaccine acceptance and considerable hesitancy among PLWH. To further increase vaccine uptake and address any remaining hesitancy in this at-risk population, targeted public health strategies and ongoing research are necessary. Strengthening vaccine acceptance is critical to safeguarding PLWH against emerging infectious diseases such as Mpox.

Clinical trial number: Not applicable.

PubMed Disclaimer

Conflict of interest statement

Declarations. Ethics approval and consent to participate: Not applicable, as there were no human participants involved in this study. Human Ethics and Consent to Participate Declarations: Not applicable. This study did not involve human subjects, so Human Ethics and Consent to Participate declarations are not required. Consent for Publication: Not applicable, as this study does not involve any individual person’s data in any form. Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
PRISMA Flow Diagram
Fig. 2
Fig. 2
A forest plot illustrating the acceptance rates of the Mpox vaccine
Fig. 3
Fig. 3
Forest plot depicting the pooled estimate of Mpox vaccine hesitancy
Fig. 4
Fig. 4
Leave-one-out analysis of the vaccine acceptance for Mpox
Fig. 5
Fig. 5
Leave-one-out analysis of the vaccine hesitancy for Mpox
Fig. 6
Fig. 6
Doi plot illustrating publication bias
See this image and copyright information in PMC

References

    1. Karagoz A, Tombuloglu H, Alsaeed M, Tombuloglu G, AlRubaish AA, Mahmoud A, et al. Monkeypox (mpox) virus: classification, origin, transmission, genome organization, antiviral drugs, and molecular diagnosis. J Infect Public Health. 2023;16(4):531–41. - PMC - PubMed
    1. Mercer J, Helenius A. Virus entry by macropinocytosis. Nat Cell Biol. 2009;11(5):510–20. - PubMed
    1. Helenius A. Virus entry: looking back and moving forward. J Mol Biol. 2018;430(13):1853–62. - PMC - PubMed
    1. Upadhyay S. Testing viral infections. Viral infections and antiviral therapies. Elsevier; 2023. pp. 99–120.
    1. Zammitt N, Sandilands E. Essentials of Kumar and Clark’s clinical medicine E-Book: essentials of Kumar and Clark’s clinical medicine. E-Book: Elsevier Health Sciences; 2021.

MeSH terms

LinkOut - more resources